Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126191 | 0.93 | RAB9A (0.43) | NPC1LMNACRBNCYP3A4RAB9A | |
| SCHEMBL20126233 | 0.85 | RAB9A (0.41) | NPC1LMNACRBNCYP3A4RAB9A | |
| SCHEMBL20126188 | 0.84 | NPC1 (0.42) | NPC1LMNACRBNCYP3A4CYP2D6 | |
| SCHEMBL20126310 | 0.84 | NPC1 (0.42) | NPC1LMNACRBNCYP3A4CYP2D6 | |
| SCHEMBL20126120 | 0.84 | RAB9A (0.37) | NPC1LMNACRBNCYP3A4RAB9A | |
| SCHEMBL20126211 | 0.80 | ALDH1A1 (0.43) | NPC1LMNACRBNCYP3A4CYP2D6 | |
| SCHEMBL20126119 | 0.80 | NPC1 (0.39) | NPC1LMNACRBNCYP3A4CYP2D6 | |
| SCHEMBL20126147 | 0.79 | CYP3A4 (0.38) | NPC1LMNACRBNCYP3A4CYP2D6 | |
| SCHEMBL20126332 | 0.77 | ALDH1A1 (0.45) | NPC1LMNACYP3A4CYP2D6RAB9A | |
| SCHEMBL20126144 | 0.76 | CRBN (0.34) | NPC1LMNACRBNCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | NPC1 4011/4885LMNA 1907/4885CRBN 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.